臨床泌尿器科73巻9号

2019年08月発行

特集 ここまで見える！　泌尿器科における可視化の進歩

〈機器の発達〉

PET/CT検査による泌尿器腫瘍の病変検出能および腫瘍活性評価能

著者： 福嶋善光¹² 汲田伸一郎²

所属機関： ¹日本医科大学健診医療センター ²日本医科大学放射線医学

ページ範囲：P.615 - P.625

文献概要

▶ポイント

・FDG-PET/CTは前立腺癌，腎癌の病期診断，悪性度評価，治療効果判定，再発診断に有効である．

・PSMA-PET/CTは前立腺癌，腎癌の病変検出能がFDG-PET/CTに比し高い．

・半導体PET/CT装置は従来のアナログ装置に比し空間分解能，S/N比，コントラスト分解能が高く，病変検出能，腫瘍活性評価能が高い．

参考文献

1） Jadvar H : FDG PET in prostate cancer. PET Clin 4 : 155-161, 2009

2） van der Vos CS, Koopman D, Rijnsdorp S, et al : Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET. Eur J Nucl Med Mol Imaging 44 （Suppl 1） : 4-16, 2017

3） Bertagna F, Piccardo A, Dib B, et al : Multicentre study of 18F-FDG-PET/CT prostate incidental uptake. Jpn J Radiol 33 : 538-546, 2015

4） Arimoto MK, Higashi T, Nishii R, et al : 11C-methylaminoisobutyric acid （MeAIB） PET for evaluation of prostate cancer : compared with 18F-fluorodeoxyglucose PET. Ann Nucl Med 30 : 553-562, 2016

5） O JH, Lodge MA and Wahl RL : Practical PERCIST : A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 280 : 576-584, 2016

6） Beauregard JM, Blouin AC, Fradet V, et al : FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging 15 : 2, 2015

7） Evangelista L, Bertoldo F, Boccardo F, et al : Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer : current modalities and new horizons. Eur J Nucl Med Mol Imaging 43 : 1546-1562, 2016

8） Calais J, Cao M and Nickols NG : The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. J Nucl Med 59 : 557-567, 2018

9） Chung YH, Tsai CK, Wang CC, et al : Early Response Monitoring Following Radiation Therapy by Using 18F-FDG and 11C-acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration. Molecules 22 : 1946, 2017

10） Schöder H, Herrmann K, Gönen M, et al : 2-［18F］ Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-specific Antigen Relapse after Radical Prostatectomy. Clin Cancer Res 11 : 4761-4769, 2005

11） Shiiba M, Ishihara K, Kimura G, et al : Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med 26 : 138-145, 2012

12） Schuster DM, Nanni C and Fanti S : Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. J Nucl Med 57 （Suppl 3） : 61S-66S, 2016

13） Schuster DM, Taleghani PA, Nieh PT, et al : Characterization of primary prostate carcinoma by anti-1-amino-2-［（18）F］ -fluorocyclobutane-1-carboxylic acid （anti-3-［（18）F］ FACBC） uptake. Am J Nucl Med Mol Imaging 3 : 85-96, 2013

14） Turkbey B, Mena E, Shih J, et al : Localized prostate cancer detection with 18F FACBC PET/CT : comparison with MR imaging and histopathologic analysis. Radiology 270 : 849-856, 2014

15） Odewole OA, Tade FI, Nieh PT, et al : Recurrent prostate cancer detection with anti-3-［（18）F］ FACBC PET/CT : comparison with CT. Eur J Nucl Med Mol Imaging 43 : 1773-1783, 2016

16） Barrio M, Fendler WP, Czernin J, et al : Prostate specific membrane antigen （PSMA） ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn 16 : 1177-1188, 2016

17） Calais J, Fendler WP, Herrmann K, et al : Comparison of 68Ga-PSMA-11 and 18F-fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J Nucl Med 59 : 789-794, 2018

18） Dietlein F, Kobe C, Neubauer S, et al : PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med 58 : 947-952, 2017

19） Perera M, Papa N, Christidis D, et al : Sensitivity, Specificity, and Predictors of Positive 68Ga-prostate-Specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer : A Systematic Review and Meta-analysis. Eur Urol 70 : 926-937, 2016

20） Pyka T, Okamoto S, Dahlbender M, et al : Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43 : 2114-2121, 2016

21） Rahbar K, Schmidt M, Heinzel A, et al : Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer : A Multicenter Retrospective Analysis. J Nucl Med 57 : 1334-1338, 2016

22） Kratochwil C, Bruchertseifer F, Giesel FL, et al : 225Ac-PSMA-617 for PSMA-targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 57 : 1941-1944, 2016

23） Eiber M, Maurer T, Souvatzoglou M, et al : Evaluation of hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56 : 668-674, 2015

24） Wang HY, Ding HJ, Chen JH, et al : Meta-analysis of the diagnostic performance of 18F-FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 12 : 464-474, 2012

25） Miyakita H, Tokunaga M, Onda H, et al : Significance of 18F-fluorodeoxyglucose positron emission tomography （FDG-PET） for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 （GLUT-1） expression in the cancer. Int J Urol 9 : 15-18, 2002

26） Noda Y, Kanematsu M, Goshima S, et al : 18-F fluorodeoxyglucose uptake in positron emission tomography as a pathological grade predictor for renal clear cell carcinomas. Eur Radiol 25 : 3009-3016, 2015

27） Gerety EL, Lawrence EM, Wason J, et al : Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol 26 : 2113-2118, 2015

28） Kayani I, Avril N, Bomanji J, et al : Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17 : 6021-6028, 2011

29） Bertagna F, Motta F, Bertoli M, et al : Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma. Nucl Med Rev Cent East Eur 16 : 3-8, 2013

30） Raveenthiran S, Esler R, Yaxley J, et al : The use of （68） Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging, 2019 Jul 23 ［Epub ahead of print］

31） Yin Y, Campbell SP, Markowski MC, et al : Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted ［（18）F］ DCFPyL PET/CT. Mol Imaging Biol 21 : 567-573, 2019

32） Meyer AR, Carducci MA, Denmeade SR, et al : Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med 33 : 617-623, 2019

33） van Sluis J, de Jong J, Schaar J, et al : Performance characteristics of the digital Biograph Vision PET/CT system. J Nucl Med 60 : 1031-1036, 2019

34） van Sluis J, Boellaard R, Somasundaram A, et al : Image quality and semi-quantitative measurements of the Siemens Biograph Vision PET/CT : Initial experiences and comparison with Siemens Biograph mCT PET/CT. J Nucl Med, 2019 Jun 28 ［Epub ahead of print］